关键词: 胃癌, 转化治疗, 腹腔灌注, 免疫治疗

Abstract: The transformation therapy for stage Ⅳ gastric cancer has become a current research hotspot. For patients with advanced gastric cancer undergoing conversion therapy, R0 resection surgery should be attempted; For tumor lesions that are difficult to cure after evaluation, it is recommended to continue drug treatment and avoid palliative resection of R1 or R2 as much as possible. For stage Ⅳ gastric cancer patients with combined peritoneal metastasis, in addition to systemic chemotherapy, the combination of intraperitoneal infusion chemotherapy and immunotherapy has also become a research focus. At present, most conclusions are mainly based on small sample retrospective studies, and some studies have not distinguished between conversion therapy and neoadjuvant therapy. Therefore, there is an urgent need for large-scale prospective randomized controlled trials to further validate. In addition, advanced gastric cancer has high heterogeneity and significant individual differences. The molecular pathological characteristics between primary and metastatic lesions vary, requiring a deep understanding of epigenetics, genomics, and proteomics information in gastric cancer to guide individualized treatment for patients.  

Key words: gastric cancer, conversion therapy, intraperitoneal infusion , immunotherapy